In Brief This Week: Agendia; Gen-Probe, Neogen; Synthetic Biology Industry Association; Biodesign Institute, Intel | GenomeWeb

NEW YORK (GenomeWeb News) – Agendia this week said that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the firm's MammaPrint test. It said patients in the US can now submit claims for the MammaPrint test directly to Palmetto GBA in California where the test results are analyzed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.